Huilin Tang

University of Florida Department of Pharmaceutical Outcomes and Policy

EvidPro,LLC (Consultant/Advisory Board)

Poster(s):

• (P-288) Novel Glucose-lowering Agents and Cardiorenal Benefits: Absence of Racial/ethnic Diversity in Clinical Trials

• (P-289) Drug-induced Liver Injury Associated with Lopinavir-ritonavir in Patients with COVID-19: A Disproportionality Analysis of U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) Data